← Leaderboards
Chris Case
Leidos Biomedical Research, Inc.
$2,800,079
Attributed
$2,800,079
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2.8M · FY2018–22$5M$3.8M$2.5M$1.3M$0
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$2,800,079 · 2
By mechanism
N01$2,800,079 · 2
Top collaborators
No co-investigators on record.
Most similar at Leidos Biomedical Research, Inc.
Same institution · by research overlap
- David Heimbrook$2,362,140,846
- Leonard Freedman$1,216,107,431
- Beth Baseler$335,223,481
- David Lindsay$51,337,878
- Lynn Briscoe$495,968,635
Others in their field
Other Emerging Leaders on “Bispecific Antibodies”
- Sarah Marie Cheal · Weill Medical Coll Of Cornell Univ$3,410,761
- Ruian Ke · Triad National Security, Llc$2,961,350
- Wen Jiang · Ut Southwestern Medical Center$2,931,879
- Paul Mathew · Tufts Medical Center$2,410,363
- Kendra S. Carmon · University Of Texas Hlth Sci Ctr Houston$2,144,957
- George G Wu · Amberstone Biosciences, Inc.$1,549,976
Research focus
Bispecific AntibodiesCommunicable DiseasesDisease OutbreaksEbolaFutureLeadMissionNational Institute Of Allergy And Infectious DiseasePandemic DiseasePreventionProduct DevelopmentProductionReagentResearch And DevelopmentRna VaccineTechnology TransferVaccine AntigenVaccine DevelopmentVaccine-Induced Antibodies